Microbion Biosciences is a Bozeman, Montana, USA, biotechnology that is developing a new class of antibiotics....
Fantastic news! We've Found the answer you've been seeking!
Question:
Transcribed Image Text:
Microbion Biosciences is a Bozeman, Montana, USA, biotechnology that is developing a new class of antibiotics. The primary market that Microbion intends to develop is the diabetic foot ulcer (DFU) market for North America. The International Diabetes Federation Atlas indicates that in 2015 there were 44 million people in North America with diabetes, and this population is expected to grow to 61 million in 2040. Microbion's studies indicate that about 10% of people with diabetes in North America develop chronic foot ulcers and would benefit from their product. Microbion believes that it will successfully have a DFU product on the market by Jan 1, 2019. The total market unit sales in 2019 is forecast to be 440,000 units, and Microbion believes that it can get 20% of that total market. Microbion forecasts that total market size will increase by 1.5% each year through at least 2040. Unfortunately, Microbion's patent protection expires on December 31, 2026, so Microbion expects to have only 7 years of patent protection for its product. Upon the expiration of the patent, generics are expected to enter the market and decrease the market price of the product such that cash flows after the patent expiration will have zero net present value. The expected product price for the Microbion DFU product is $1200, and that price is expected to hold through Microbion's patent protection period which ends at the end of 2026 (although inflation would be expected to push prices up, the market power of federal government is expected to keep prices constant). Prices will adjust downward in 2027 when generics enter the market. The total costs of goods sold of producing the product are 20% of sales, and the sales, general and administrative expenses are expected to be 30% of sales. In order to continue with this project, Microbion will need to invest $21,000,000 on January 1, 2017 for the Phases 3 study which is expected to be completed in September 2017. This investment will be depreciated on a straight line basis for 7 years (through 2025), but the first year of depreciation will not occur until 2019, which is the first year of positive revenue. In addition, Microbion will need to increase the Net Working Capital of the company in 2019 by $2,000,000. These funds WILL NOT be returned at the end of the project. The probability that Microbion will successfully complete the Phase 3 study and have its DFU product accepted for the market is 75%. You have done sufficient due diligence on the numbers that Microbion has provided and have confirmed from your own sources that they are appropriate. You have determined that the appropriate cost of capital for this project is 18%. The corporate tax rate for Microbion is 35%. You also know that a multiplier of 1.2 times last year's sales is a multiplier used for valuation in the antibiotic industry. Based on the information that you have already collected and any assumptions that you need to make, determine a valuation for Microbion as if it is January 1, 2017. Clearly explain and justify how you arrived at this valuation. Discuss the different valuation approaches that are available to you, and explain why you used the approach(es) that you used. Microbion Biosciences is a Bozeman, Montana, USA, biotechnology that is developing a new class of antibiotics. The primary market that Microbion intends to develop is the diabetic foot ulcer (DFU) market for North America. The International Diabetes Federation Atlas indicates that in 2015 there were 44 million people in North America with diabetes, and this population is expected to grow to 61 million in 2040. Microbion's studies indicate that about 10% of people with diabetes in North America develop chronic foot ulcers and would benefit from their product. Microbion believes that it will successfully have a DFU product on the market by Jan 1, 2019. The total market unit sales in 2019 is forecast to be 440,000 units, and Microbion believes that it can get 20% of that total market. Microbion forecasts that total market size will increase by 1.5% each year through at least 2040. Unfortunately, Microbion's patent protection expires on December 31, 2026, so Microbion expects to have only 7 years of patent protection for its product. Upon the expiration of the patent, generics are expected to enter the market and decrease the market price of the product such that cash flows after the patent expiration will have zero net present value. The expected product price for the Microbion DFU product is $1200, and that price is expected to hold through Microbion's patent protection period which ends at the end of 2026 (although inflation would be expected to push prices up, the market power of federal government is expected to keep prices constant). Prices will adjust downward in 2027 when generics enter the market. The total costs of goods sold of producing the product are 20% of sales, and the sales, general and administrative expenses are expected to be 30% of sales. In order to continue with this project, Microbion will need to invest $21,000,000 on January 1, 2017 for the Phases 3 study which is expected to be completed in September 2017. This investment will be depreciated on a straight line basis for 7 years (through 2025), but the first year of depreciation will not occur until 2019, which is the first year of positive revenue. In addition, Microbion will need to increase the Net Working Capital of the company in 2019 by $2,000,000. These funds WILL NOT be returned at the end of the project. The probability that Microbion will successfully complete the Phase 3 study and have its DFU product accepted for the market is 75%. You have done sufficient due diligence on the numbers that Microbion has provided and have confirmed from your own sources that they are appropriate. You have determined that the appropriate cost of capital for this project is 18%. The corporate tax rate for Microbion is 35%. You also know that a multiplier of 1.2 times last year's sales is a multiplier used for valuation in the antibiotic industry. Based on the information that you have already collected and any assumptions that you need to make, determine a valuation for Microbion as if it is January 1, 2017. Clearly explain and justify how you arrived at this valuation. Discuss the different valuation approaches that are available to you, and explain why you used the approach(es) that you used.
Expert Answer:
Answer rating: 100% (QA)
To determine the valuation for Microbion as of January 1 2017 we can use a combination of valuation approaches including the discounted cash flow DCF ... View the full answer
Related Book For
Posted Date:
Students also viewed these accounting questions
-
Managing Scope Changes Case Study Scope changes on a project can occur regardless of how well the project is planned or executed. Scope changes can be the result of something that was omitted during...
-
Read the case study "Southwest Airlines," found in Part 2 of your textbook. Review the "Guide to Case Analysis" found on pp. CA1 - CA11 of your textbook. (This guide follows the last case in the...
-
Planning is one of the most important management functions in any business. A front office managers first step in planning should involve determine the departments goals. Planning also includes...
-
On 1 June 1998, Alice bought a house in Derby for 45,000. - She occupied the house as her PPR until 1 May 2000 when she left to work in Exeter, living in rented accommodation. - She returned to the...
-
A 6-kg object is pulled along a frictionless horizontal surface by a horizontal force of 10 N. (a) If the object is at rest at t = 0, how fast is it moving after 3 s? (b) How far does it travel...
-
A double-slit barrier with slit separation distance \(d\) is a distance \(L\) from a screen, with \(L \gg d\). When green laser light \(\left(\lambda_{\mathrm{g}}=532 \mathrm{~nm} ight)\) passes...
-
Which of the following is not a control activity? a. Mandatory vacations b. Risk assessment C. Security measures d. Proper authorization
-
The Evanstonian is an upscale independent hotel that caters to both business and leisure travelers. On aver-age, one- third of the guests checking in each day are leisure travelers. Leisure travelers...
-
Which of the tenets in Howard Gardner's (Harvard) recommendations regarding "How Education Changes" describes what students need to learn in a globalized world related to the need for students to be...
-
D. Deni commenced business on 1 April 2014 by depositing Sh.8 million into the business bank account. All receipts and payments were channelled through this business account. During the year ended 31...
-
A company is all-equity financed at a cost of 9%. Its tax rate is 35%. Capital markets are perfect, except for the existence of corporate income taxes. 1. Compute its WACC 2. How would the CoE change...
-
Fairness, justice, and equity must be at the forefront of every organization's strategic plan. Yet many still treat these qualities as merely secondary to organizational performance - something to...
-
What strategies and tools can Agile practitioners employ to effectively prioritize and manage project backlogs, ensuring that features are sequenced based on business value, risk mitigation, and...
-
Commercial Drone Inc. engaged a vendor on a Cost Plus Incentive Fee contract where the vendor was promised to be reimbursed for the cost estimated at $980,000 and the target fee is $105,000. Any cost...
-
When needs conflicts occur, both parties are not aware of the other party's needs. What would be the best option for resolving this type of conflict? Explain.
-
Your grandpa has $550,000 in his account and he needs to receive monthly payments of $55,000. If he receives the payments at the end of the month, and the current interest rate is 17 percent,...
-
Fred and Ethel are going to take out a business loan on which they will make annual payments of $7,500 for six years. At that point in time they will also pay off the remaining balance which will be...
-
(a) Given a mean free path = 0.4 nm and a mean speed vav = 1.17 105 m/s for the current flow in copper at a temperature of 300 K, calculate the classical value for the resistivity of copper. (b)...
-
On March 1, Midway Distribution Company is considering leasing a building and buying the necessary equipment to operate a public warehouse. Alternatively, the company could use the funds to invest in...
-
Using the data in Exercise 6-10, assume that during the second year of operations Master Plumbing Supply Co. had net sales of $4,200,000, wrote off $60,000 of accounts as uncollectible using the...
-
Financial information related to Joshua Tree Interiors for August and September 2010 is as follows: a. Prepare balance sheets for Joshua Tree Interiors as of August 31 and as of September 30, 2010.b....
-
Refer to Problem 3-56B. 1. Use the For You eTravel Inc. data in problem P3-56B to prepare the company's classified balance sheet at December 31, 2020. Show captions for total assets, total...
-
The accounts of For You eTravel Inc. at December 31, 2020, are listed in alphabetical order. Requirements 1. All adjustments have been journalized and posted, but the closing entries have not been...
-
The adjusted trial balance of Reid and Campbell Ltd. at December 31, 2020, appears below. Requirements 1. Prepare Reid and Campbell Ltd.'s 2020 income statement, statement of retained earnings, and...
Study smarter with the SolutionInn App